The immune checkpoint therapy upregulated the transcription factor DEC1 in tumor antigen-specific CD8+ and CD4+ T cells, while DEC1 deficiency inhibited immune checkpoint therapy-induced macrophage transformation from M2 to M1 subtype[36]. This evidence concerns the gene CD8A and neoplasm.